Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.

3 Jun 2015

El Camino Hospital enrolls first patient in safety study using RenovoCath

El Camino Hospital in Mountain View, California has enrolled the first patient in a safety study using the RenovoCath, a new catheter that is being introduced for targeted delivery of fluids to selected sites in the peripheral vascular system. The study will help physicians determine appropriate dosing of locally-delivered chemotherapy for patients with pancreatic cancer.

3 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

NCCN to host policy summit on emerging issues in tissue allocation

Tissue allocation is a growing issue of concern for many researchers due, in part, to expanding research interests in precision medicine. The increased demand by pharmaceutical and biotech companies for patient tissue specimens collected for clinical care and trials presents clinical, ethical, and legal issues.

2 Jun 2015

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer.

1 Jun 2015

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.

1 Jun 2015

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.

30 May 2015

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20

30 May 2015

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

TGen professor to receive top award from Arizona Medical Association

Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute, will receive one of the top awards May 29 from the Arizona Medical Association.

24 May 2015

Stereotactic body radiotherapy appears to be safe, effective for some pancreatic cancer patients

Two studies from Johns Hopkins Kimmel Cancer Center researchers add to preliminary evidence that high-dose radiation treatment, called stereotactic body radiotherapy, appears to be safe and as effective as standard radiation treatment for certain patients with pancreatic cancer whose tumors are advanced but have not spread.

20 May 2015

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

An international team led by Weill Cornell Medical College investigators has illuminated the precise molecular steps that enable pancreatic cancer to spread to the liver -- the event that makes the most common form of the disease lethal. By understanding this process, investigators say their discovery can lead to targeted treatments that delay metastasis, and could offer clinicians a new biomarker to test for the earliest signs of pancreatic cancer.

19 May 2015

Obese people at greater risk of developing cancer

Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this coming Saturday (16 May), metabolic expert Alexandra Kautzky-Willer, Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital, draws attention to the fact that, even in Austria, more and more people are suffering from obesity.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.

6 May 2015

Pancreatic Cancer News and Research

Further Reading

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

El Camino Hospital enrolls first patient in safety study using RenovoCath

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

NCCN to host policy summit on emerging issues in tissue allocation

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

TGen professor to receive top award from Arizona Medical Association

Stereotactic body radiotherapy appears to be safe, effective for some pancreatic cancer patients

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

Obese people at greater risk of developing cancer

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News